Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 3/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | LOX | P28300 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26164133 | 0.84 | HSP90AA1 (0.40) | HSP90AA1HSP90AB1ALDH1A1FGFR1RAB9A | |
| SCHEMBL3272205 | 0.75 | CYP3A4 (0.53) | HSP90AA1HSP90AB1ALDH1A1FGFR1RAB9A | |
| SCHEMBL22951350 | 0.74 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL20033972 | 0.72 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1ALDH1A1FGFR1RAB9A | |
| SCHEMBL26164132 | 0.72 | RAB9A (0.51) | HSP90AA1HSP90AB1ALDH1A1RAB9ANOS1 | |
| SCHEMBL5172891 | 0.71 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1ALDH1A1FGFR1RAB9A | |
| SCHEMBL26164131 | 0.71 | HTT (0.44) | HSP90AA1HSP90AB1ALDH1A1FGFR1RAB9A | |
| SCHEMBL544333 | 0.71 | NOS1 (0.42) | HSP90AA1HSP90AB1FGFR1RAB9AHTT | |
| SCHEMBL12769723 | 0.71 | ATM (0.44) | ALDH1A1CYP3A4LOX | |
| SCHEMBL28274098 | 0.71 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1ALDH1A1FGFR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | HSP90AA1 765/4885HSP90AB1 563/4885ALDH1A1 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.